|
|
 |
|
Viewing report
|
|
|
|
Acute Upper Respiratory Infections (AURI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, April 2011, Pages: 72
Acute Upper Respiratory Infections (AURI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData has released its new report, “Acute Upper Respiratory Infections (AURI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global AURI market. The report identifies the key trends shaping and driving the global AURI market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global AURI sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
The global Acute Upper Respiratory Infection (AURI) market was valued at $692m in 2010 and is forecast to show slow growth at a compound annual growth rate (CAGR) of 1.3% to reach $755m by 2017. The growth will primarily be driven by an increase in the general population and depleting environmental conditions, which can increase the incidence of the disease. At present, the market has a lot of approved therapies (many of them with generics) and a lot of off-label drugs in the market. As the disease is self-limited and there are plenty of available therapies with good efficacy and safety profiles, there is a low unmet need in the market.
Scope
The report provides information on the key drivers and challenges of the AURI market. Its scope includes -
- Annualized global AURI market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as are topoisomerase II and topoisomerase IV inhibitor, PDE-IV inhibitor and a-1 selective agonist/H1 receptors antagonist.
- Analysis of the current and future competition in the global AURI market. Key market players covered are GlaxosmithKline, Dong Wha Pharma/IASO Pharma Inc., Edmond Pharma Srl and Ache Laboratorios Farmaceuticos S.A.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the AURI therapeutics market.
- Analysis of key recent licensing and partnership agreements in AURI therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global AURI market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global AURI market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global AURImarket landscape? – Identify, understand and capitalize
|
|
|
|
